Summary
RV7 Chart
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.
Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge
Halozyme Therapeutics is entering a powerful earnings inflection, driven by surging royalty revenue and strategic acquisitions expanding its drug delivery platform. FY25 revenue grew 38% to $1.397 billion, with royalty revenue up 52%; recent acquisitions extend IP life and diversify the technology portfolio. 2026 guidance targets $1.71–$1.81 billion in revenue, over 70% EBITDA growth, and nearly 100% EPS growth, highlighting operating leverage and platform scalability.
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics Inc. (RV7) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Halozyme Therapeutics Inc. ever had a stock split?
Halozyme Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Helen I. Torley CEO | XBER Exchange | US40637H1095 ISIN |
| US Country | 350 Employees | - Last Dividend | - Last Split | 16 Mar 2004 IPO Date |
Overview
Halozyme Therapeutics, Inc. is a pioneering biopharma technology platform company engaged in the research, development, and commercialization of proprietary enzymes and devices globally, including in the United States, Switzerland, Belgium, Japan, and other international markets. At the core of its product offering is the patented recombinant human hyaluronidase enzyme (rHuPH20), a transformative component that permits the delivery of injectable biologics, like monoclonal antibodies and various therapeutic molecules, as well as small molecules and fluids. Founded in 1998 and based in San Diego, California, Halozyme is at the forefront of enhancing drug delivery mechanisms, aiming to improve outcomes for patients across a myriad of diseases.
Products and Services
- Hylenex recombinant: A formulation of rHuPH20 aimed at facilitating subcutaneous (SC) fluid administration. It is used to achieve hydration, enhance the dispersion and absorption of other injected drugs in SC urography, and enhance the resorption of radiopaque agents.
- HIV Treatments (rilpivirine, cabotegravir, and N6LS BNAB): These products are aimed at the treatment of HIV, exhibiting Halozyme's versatility in addressing viral diseases.
- Ocrelizumab: Developed for the treatment of multiple sclerosis, showcasing Halozyme's commitment to tackling autoimmune and neurodegenerative diseases.
- XYOSTED: An injection for SC administration of testosterone, serving as a replacement therapy.
- ATRS-1902: A proprietary drug device combination product, highlighting Halozyme's innovation in drug delivery systems.
- Cancer Treatments (Herceptin, Herceptin Hylecta, Phesgo, Mabthera SC, HYQVIA, and DARZALEX): A range of products for various forms of cancer, including breast cancer, chronic lymphocytic leukemia, primary immunodeficiency disorders, amyloidosis, smoldering myeloma, and multiple myeloma. These examples emphasize Halozyme's significant presence in the oncology sector.
- Epinephrine Injection: Aimed at treating allergic reactions, this product highlights Halozyme's dedication to emergency medicine.
- Solid Tumor Treatments (nivolumab+relatlimab and ANTI-TIM3): These treatments are for solid tumors, showcasing Halozyme's efforts in expanding its oncology portfolio.
- ARGX-117: Developed for multifocal motor neuropathy, further demonstrating Halozyme's focus on rare neurological conditions.
- Immunosuppressive Treatments (atezolizumab, nivolumab, afgartigimod): These are aimed at treating autoimmune diseases, showing Halozyme's role in developing therapies for immune system disorders.
- Teriparatide Injections and OTREXUP: Products like these, aimed at severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis, underscore the company's commitment to chronic disease management.
- ATRS-1902 for adrenal crisis rescue, together with ARGX-113; and ARGX-117 for severe autoimmune diseases: These products illustrate Halozyme's dedication to addressing acute and chronic conditions with innovative delivery systems and therapeutic agents.
